BTIG lowered the firm’s price target on Biohaven (BHVN) to $33 from $60 and keeps a Buy rating on the shares. In a broader research note previewing Q3 results for select biotech names, the firm is updating its assumptions and models for the company, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN: